Aldeyra Therapeutics Inc. (ALDX)

11.92
NASDAQ : Health Technology
Prev Close 12.42
Day Low/High 11.90 / 12.64
52 Wk Low/High 5.55 / 16.70
Avg Volume 635.10K
Exchange NASDAQ
Shares Outstanding 26.09M
Market Cap 324.06M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Aldeyra Therapeutics Announces Positive Results From Phase 2b Dry Eye Disease Clinical Trial

Aldeyra Therapeutics Announces Positive Results From Phase 2b Dry Eye Disease Clinical Trial

Statistically Significant Improvement Across Multiple Symptom and Sign Measures

Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results And Provides Corporate Update

Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results And Provides Corporate Update

Phase 2b Results for Topical Ocular Reproxalap in Dry Eye Disease Expected in Late Third Quarter or Early Fourth Quarter 2018

Aldeyra Therapeutics Appoints Joshua Reed As Chief Financial Officer

Aldeyra Therapeutics Appoints Joshua Reed As Chief Financial Officer

LEXINGTON, Mass., July 31, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.

Oversold Conditions For Aldeyra Therapeutics (ALDX)

Oversold Conditions For Aldeyra Therapeutics (ALDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aldeyra Therapeutics Announces First Patient Enrolled In Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial

Aldeyra Therapeutics Announces First Patient Enrolled In Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial

LEXINGTON, Mass., July 24, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Announces Last Patient Dosed In Dry Eye Disease Phase 2b Clinical Trial

Aldeyra Therapeutics Announces Last Patient Dosed In Dry Eye Disease Phase 2b Clinical Trial

LEXINGTON, Mass., July 12, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Announces Development Programs At 2018 Research Day

Aldeyra Therapeutics Announces Development Programs At 2018 Research Day

Expanded Pipeline Features Distinct Mechanisms of Action Across Five Product Candidates

Aldeyra Therapeutics Joins The Russell 3000® And 2000® Indexes

Aldeyra Therapeutics Joins The Russell 3000® And 2000® Indexes

LEXINGTON, Mass., June 25, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Announces 2018 Research Day

Aldeyra Therapeutics Announces 2018 Research Day

LEXINGTON, Mass., June 20, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results At The Association For Research In Vision And Ophthalmology 2018 Annual Meeting

Data Demonstrate Statistically and Clinically Significant Activity of Topical Ocular 0.1% Reproxalap Across a Broad Array of Signs and Symptoms

2 Small Biopharmas With Case of 'Hiccups'

2 Small Biopharmas With Case of 'Hiccups'

Insiders are taking advantage of opportunities in Intra-Cellular Therapies and Aldeyra.

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

The Lexington, Mass.-based company unveiled results from its Phase 2a study of ADX-102 in dry eye disease. Other biotech movers in premarket trading on Sept. 12 include Sage Therapeutics and Intercept Pharmaceuticals.

Aldeyra Therapeutics To Present At The Cowen And Company 36th Annual Health Care Conference

Aldeyra Therapeutics To Present At The Cowen And Company 36th Annual Health Care Conference

Presentation to Include Additional Data From Aldeyra's Recently Completed Phase IIa Clinical Trial of NS2 in Allergic Conjunctivitis